Abstract:Purpose/Objective(s) Mucosal melanoma of the head and neck is a rare and deadly disease. The optimal treatment for mucosal melanoma remains uncertain, and there is no consensus on the most effective treatment approach, including the extent of surgical resection, the use of adjuvant therapy, and the role of immunotherapy. Current controversies and unknowns about disease treatment and outcomes stem from the rarity of mucosal melanoma, the lack of large-scale clinical trials, and the heterogeneity of the disease. This study aims to determine the survival benefit of immunotherapy, surgery and radiation in setting of mucosal melanoma. Materials/Methods We extracted data from NCDB database with histology codes (ICD-O 2 melanoma codes M872–M879) for patients with mucosal melanoma diagnosed from year 2000-2020 with a total sample size 3937. The patients’ characteristics were summarized by median and interquartile range (IQR) for a continuous variable and by frequency and percentage for a categorical variable. We considered the different combinations of treatments in terms of surgery, chemotherapy, radiation therapy, and immunotherapy. The outcome variables are (1) time to death since diagnosis, and (2) death. Kaplan-Meier survival estimates were used. The log-rank test was employed to compare the survival distributions of the different treatment groups. Cox Proportional Hazard Regression model was performed to evaluate the association between the treatment combinations and survival outcome, adjusting the clinical and demographic variables (e.g., sex, age, stage of cancer). Hazard ratio (HR) and 95% confidence interval (CI) were reported. Mortality rate for each treatment combination was also reported, and the multiple logistic regression model was used to examine the effect of different treatment on mortality. Results The median overall survival (OS) time for all patients diagnosed with mucosal melanoma was 25.7 months. Among them, 50.1% were males, 9.4% younger than 50 years old and 50.6% older than 70, 88.7% white, and 57.6% with Medicare. Cox proportional hazard model showed that the survival time is significantly associated with the following factors: age group 60-70 (HR 1.25, 95%CI [1.06, 1.48]) and >70 (HR 1.83, 95%CI [1.56, 2.13]) comparing with age group <50. Male sex increased the risk of death (HR 1.13, 95%CI[1.04, 1.22]). Surgery decreased the risk of death (HR 0.49, 95%CI [0.44, 0.55]). The use of radiation and immunotherapy had no association with survival. Chemotherapy increased the risk of death (HR 1.33, 95%CI [1.18,1.51]), and was associated with more advanced age and high tumor stage. The multiple logistic regression model showed similar impact of these factors on mortality. Conclusion Treatment paradigms for mucosal melanoma vary widely. Local therapy remains important for improved survival. Further analyses should be done to explore the benefits of multi-modality treatment.

Combined Treatment of Oral Mucosal Malignant Melanoma with 73 Cases in Chinese Experience

Oral Mucosa Melanomas: 21 Cases Report and Review of the Literature

Clinical analysis of 19 cases of oral mucosal malignant melanoma

Retrospective Analysis of Primary Malignant Melanoma Located Oral Maxillofacial Region

Clinical analysis of 51 cases of oral mucosal melanoma

Neck Dissection and Post-Operative Chemotherapy with Dimethyl Triazeno Imidazole Carboxamide and Cisplatin Protocol Are Useful for Oral Mucosal Melanoma

[Evaluation of Cryosurgery for the Management of Oral Malignant Mucomembranous Melanoma-a Survey of 107 Cases Reports]

Clinical presentation, histology and prognosis of mucosal melanoma in ethnic Chinese: A study of 212 consecutive cases

Treatment and Prognosis of Oral Mucosal Melanoma.

Clinical Presentation, Systemic Therapy and Prognosis of Mucosal Melanoma, A Study of 463 Consecutive Cases

Local Therapy in the Management of Mucosal Melanoma: An NCDB Analysis

Primary malignant melanoma of the oral cavity - A clinicopathologic and immunohistochemical study of 32 cases

Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma.

Treatment Outcomes of Mucosal Melanoma of the Head and Neck: Analysis of 190 Cases from a Single Institution

Simultaneous Primary Mucosal Malignant Melanoma Of The Oral Cavity And Squamous Cell Carcinoma Of Scalp: A Case Report And Literature Review

Clinical outcomes and patterns of failure of head and neck mucosal melanoma treated with multiple treatment modalities

Primary Oral Mucosal Melanoma: Advocate a Wait-and-see Policy in the Clinically N0 Patient.

Clinical analysis of 29 cases of nasal mucosal malignant melanoma.

Treatment and prognosis in sinonasal mucosal melanoma: A retrospective analysis of 65 patients from a single cancer center.

Melanoma in China: A Prognostic Study of 522 Cases.

Curative effect of the 1st line and the 2nd line therapies for the 232 patients with advanced mucosal melanoma and factors efecting prognosis of the patients